Niramai's thermal-AI screening grows into a quiet diagnostics export from India

Niramai Health Analytix's radiation-free breast cancer screening technology - which uses thermal imaging cameras combined with proprietary machine-learning algorithms to detect thermographic patterns associated with early-stage malignancy - has been steadily deployed across hospitals, health camps and corporate wellness programmes in India and select overseas markets, building a clinical track record that is beginning to attract serious attention from international screening programmes seeking alternatives to conventional mammography. The Bengaluru startup, founded by Geetha Manjunath and Nidhi Mathur, is one of the more technically differentiated medtech companies to emerge from the Indian startup ecosystem, and its international traction is a useful counterpoint to the assumption that meaningful healthcare IP can only originate from well-capitalised Western research environments. The technology's clinical rationale is grounded in the biology of tumour angiogenesis. Malignant tumours develop their own blood supply, generating localised temperature differentials that thermal cameras can detect before the tumour reaches the size detectable by conventional imaging. At the same time, the radiation-free, contact-free nature of the examination eliminates the safety, privacy and physical barriers that suppress mammography uptake - particularly relevant in India, where public awareness of breast cancer screening is growing but cultural and logistical barriers to conventional mammography remain significant, especially in semi-urban and rural populations. Niramai has pursued a dual deployment strategy. In urban hospitals and corporate wellness programmes, the device operates as a premium adjunct to standard clinical protocols, offering an additional data point alongside annual health check-ups. In camp-based community screening programmes, often run in partnership with NGOs, state health departments and CSR programmes, it serves as a first-line screening tool in populations that have no access to mammography infrastructure. Each deployment generates new clinical data that Niramai feeds back into model improvement, compounding the algorithm's diagnostic accuracy over time. The overseas deployments - which span several African countries, parts of Southeast Asia and an emerging footprint in the United States through partnership agreements - are significant for both clinical validation and commercial potential. International clinical study data, collected in diverse populations with different demographic characteristics than the Indian training set, strengthens the regulatory case for the technology across multiple markets. The US deployment, while still early, has attracted attention from breast-health programmes seeking to improve equity in screening access in underserved communities. What to watch: the outcome of any regulatory filing with the FDA or European CE marking authority for the Niramai device, whether any large hospital network in the United States or Europe makes a commercial deployment commitment, and whether the clinical data emerging from African and Southeast Asian deployments supports the accuracy claims made in Indian studies.

Original source: Mint